L. Karen Smith
Affiliations
- at Sangamo Therapeutics Inc (SGMO), 2025-06-16
- Director at Context Therapeutics Inc. (CNTX), 2025-06-12
- Director at Skye Bioscience Inc. (SKYE), 2025-02-26
- Director at Aurinia Pharmaceuticals Inc. (AUPH), 2024-11-25
- Director at Talaris Therapeutics Inc. (TALS), 2023-06-14
- Chief Medical Officer at Quince Therapeutics Inc. (QNCX), 2023-02-02
- Director at Antares Pharma Inc. (ATRS), 2022-05-26
- Director at Acceleron Pharma Inc (XLRN), 2021-11-22
- Evp, Chief Medical Officer at Emergent Biosolutions Inc. (EBS), 2021-05-11
- Evp, R&D And Cmo at Jazz Pharmaceuticals Plc (JAZZ), 2018-03-07
- Director at Sucampo Pharmaceuticals Inc. (SCMP), 2018-02-13
Insider Trading: Purchases See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| JAZZ | $137.26 | 1 | $137.26 | 14,182 | 2016-08-12 | Filing |
| JAZZ | $137.10 | 607 | $83,218.24 | 14,181 | 2016-08-12 | Filing |
| JAZZ | $143.63 | 580 | $83,304.82 | 13,574 | 2016-07-13 | Filing |
| JAZZ | $149.61 | 557 | $83,335.11 | 12,994 | 2016-06-13 | Filing |
Insider Trading: Sales See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| AUPH | $8.43 | 5,241 | $44,181.63 | 12,672 | 2024-11-11 | Filing |
| XLRN | $141.15 | 641 | $90,477.15 | 1,622 | 2021-04-05 | Filing |
| XLRN | $140.13 | 11,223 | $1,572,678.99 | 2,263 | 2021-04-05 | Filing |
| XLRN | $137.92 | 941 | $129,782.72 | 4,561 | 2021-04-01 | Filing |
| XLRN | $136.92 | 3,796 | $519,748.32 | 5,502 | 2021-04-01 | Filing |